Ignite Creation Date:
2025-12-24 @ 11:39 PM
Ignite Modification Date:
2026-05-14 @ 12:58 PM
Study NCT ID:
NCT02142751
Status:
COMPLETED
Last Update Posted:
2019-08-06
First Post:
2014-05-13
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli
Sponsor:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Infection Due to ESBL Escherichia Coli | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Escherichia coli | View |
| None | Extended-spectrum β-lactamases (ESBLs) | View |
| None | Bacteremia | View |
| None | Urinary tract infection | View |
| None | Bloodstream infection | View |
| None | Fosfomycin | View |
| None | Meropenem | View |
| None | Pharmacokinetics | View |
| None | intestinal colonization | View |
| None | Recurrence | View |
| None | multidrug resistance E.coli | View |
| None | Ceftriaxone | View |